Literature DB >> 31656821

Role of lipoprotein (a) in peripheral arterial disease.

Constantine E Kosmas1, Delia Silverio2, Andreas Sourlas3, Richard Peralta1, Peter D Montan2, Eliscer Guzman1, Mario J Garcia1.   

Abstract

Entities:  

Year:  2019        PMID： 31656821      PMCID： PMC6789348          DOI： 10.21037/atm.2019.08.77

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  26 in total

1.  Lipoprotein(a), inflammation, and peripheral arterial disease in a community-based sample of older men and women (the InCHIANTI study).

Authors:  Stefano Volpato; Giovanni B Vigna; Mary M McDermott; Margherita Cavalieri; Cinzia Maraldi; Fulvio Lauretani; Stefania Bandinelli; Giovanni Zuliani; Jack M Guralnik; Renato Fellin; Luigi Ferrucci
Journal:  Am J Cardiol       Date:  2010-04-27       Impact factor: 2.778

Review 2.  Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events.

Authors:  Adam Taleb; Joseph L Witztum; Sotirios Tsimikas
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

Review 3.  A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies.

Authors:  Sotirios Tsimikas
Journal:  J Am Coll Cardiol       Date:  2017-02-14       Impact factor: 24.094

Review 4.  Lipoprotein(a): resurrected by genetics.

Authors:  F Kronenberg; G Utermann
Journal:  J Intern Med       Date:  2012-11-12       Impact factor: 8.989

5.  Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study.

Authors:  Ioanna Tzoulaki; Gordon D Murray; Amanda J Lee; Ann Rumley; Gordon D O Lowe; F Gerald R Fowkes
Journal:  Eur Heart J       Date:  2007-01-09       Impact factor: 29.983

Review 6.  Peripheral artery disease: epidemiology and global perspectives.

Authors:  F Gerry R Fowkes; Victor Aboyans; Freya J I Fowkes; Mary M McDermott; Uchechukwu K A Sampson; Michael H Criqui
Journal:  Nat Rev Cardiol       Date:  2016-11-17       Impact factor: 32.419

7.  Lp(a) lipoprotein is an independent, discriminating risk factor for premature peripheral atherosclerosis among white men.

Authors:  R J Valentine; P A Grayburn; G L Vega; S M Grundy
Journal:  Arch Intern Med       Date:  1994-04-11

8.  Lipoprotein(a) is an independent risk factor for peripheral arterial disease in Chinese type 2 diabetic patients in Taiwan.

Authors:  Chin-Hsiao Tseng
Journal:  Diabetes Care       Date:  2004-02       Impact factor: 19.112

9.  Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts.

Authors:  Anja Laschkolnig; Barbara Kollerits; Claudia Lamina; Christa Meisinger; Barbara Rantner; Marietta Stadler; Annette Peters; Wolfgang Koenig; Andrea Stöckl; Doreen Dähnhardt; Carsten A Böger; Bernhard K Krämer; Gustav Fraedrich; Konstantin Strauch; Florian Kronenberg
Journal:  Cardiovasc Res       Date:  2014-04-22       Impact factor: 10.787

10.  Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study.

Authors:  Deepti Gurdasani; Barbara Sjouke; Sotirios Tsimikas; G Kees Hovingh; Robert N Luben; Nicholas W J Wainwright; Cristina Pomilla; Nicholas J Wareham; Kay-Tee Khaw; S Matthijs Boekholdt; Manjinder S Sandhu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-10-11       Impact factor: 8.311
View more
  3 in total

1.  A case of hyperlipoprotein(a)emia undergoing catheter interventions for coronary artery disease, aortic valve stenosis, and peripheral artery disease.

Authors:  Akihiro Nakamura; Kenjiro Sato; Masateru Kondo; Hideaki Endo
Journal:  SAGE Open Med Case Rep       Date:  2022-02-07

2.  Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.

Authors:  Gregory G Schwartz; Philippe Gabriel Steg; Michael Szarek; Vera A Bittner; Rafael Diaz; Shaun G Goodman; Yong-Un Kim; J Wouter Jukema; Robert Pordy; Matthew T Roe; Harvey D White; Deepak L Bhatt
Journal:  Circulation       Date:  2020-03-29       Impact factor: 29.690

Review 3.  Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics.

Authors:  Daniel I Swerdlow; David A Rider; Arash Yavari; Marie Wikström Lindholm; Giles V Campion; Steven E Nissen
Journal:  Cardiovasc Res       Date:  2022-03-25       Impact factor: 10.787
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.